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The Effect of Green Coffee Extract Supplementation on Blood Pressure: A Systematic 
Review and Meta-Analysis of Randomized Controlled Trials  
Abstract 
Given the proliferation in studies investigating green coffee bean extract (GCBE) supplementation, 
the purpose of this study was to determine the efficacy and effectiveness of GCBE 
supplementation on indices of blood pressure. The literature search was performed in four 
databases including PubMed/Medline, Scopus, the Cochrane Library, and Google Scholar to 
identify clinical trials that examined the effects of green coffee supplements on SBP and DBP up 
to February 2019. Mean change and standard deviation (SD) of the outcome measures were used 
to estimate the mean difference between the intervention group and the control group at follow-
up. Nine studies including reported SBP and DBP as an outcome measure. Results revealed 
significant reduction in SBP (WMD: -3.093 mmHg, 95% CI: -3.914, -2.273; I2 = 0.0%) and DBP 
(-2.170 mmHg, 95% CI: -2.749, -1.590; I2= 46.5%) after green coffee supplementation with low 
heterogeneity among the studies. In addition, in sub-group analysis, a significant reduction in SBP 
and DBP in studies with hypertensive patients, green coffee dosage <400 mg, and administered 
for ≤4 weeks was identified. The results of current meta-analysis study support the use of GCBE 
supplementation for the improvement of blood pressure indices, with sub-group analysis 
highlighting improvements in hypertensive patients. 







High blood pressure is a major risk factor for cardiovascular disease (Stamler, Stamler, & Neaton, 
1993), with global prevalence varying from less than 3.4% to over 72.5% (Kearney, Whelton, 
Reynolds, Whelton, & He, 2004). In the Framingham study, the risk of developing high blood 
pressure over a lifetime was 90%, whilst it is estimated that the global burden of hypertension will 
increase to 1.56 million by 2025 (Kearney et al., 2005). Hypertension is a primary risk factor for 
CHD, CVD and can lead to stroke, kidney problems, disability and early mortality (Chen et al., 
2009). High blood pressure can be reduced by lifestyle changes such as changing diet, increasing 
physical activity, or through drug therapy (Suzuki, Kagawa, Ochiai, Tokimitsu, & Saito, 2002). 
Many studies have shown that antioxidant vitamins, supplements and many nutritional 
supplements can reduce blood pressure in humans and animals (Kazuya Kozuma, Shigemi 
Tsuchiya, Jun Kohori, Tadashi Hase, & Ichiro Tokimitsu, 2005), for example, polyphenols are 
food additives that are known as antioxidants and widely distributed in foods such as tomatoes, 
apples, chocolate, coffee and tea (Flament & Bessière-Thomas, 2002). 
Coffee is one of the most commonly consumed drinks in the world, and has been reported to elicit 
a protective effect on liver function (Johnson et al., 2011), diabetes mellitus (van Dam, 2008) and 
degenerative diseases (Gaafar, El-Ghamery, & Mahmuod, 2013). Unroasted Green Coffee is rich 
in chlorogenic acid (CGA 2-5 gr/100 gr) (Haidari, Samadi, Mohammadshahi, Jalali, & Engali, 
2017), which consists of caffeic acids or ferulic acids (Clifford, 1999), and possesses anti-diabetic 
(Meng, Cao, Feng, Peng, & Hu, 2013), anti-obesity (Cho et al., 2010; Gorji et al., 2019) and anti-
lipidemic (Cho et al., 2010; Ong, Hsu, & Tan, 2013; Salamat et al., 2019) properties, with 
Yamaguchi et al, asserting that drinking a cup of coffee daily has an antihypertensive effect 
(Yamaguchi et al., 2008). In Kuzuya et al., male, hypertensive participants who supplemented with 
Green coffee bean extract (GCBE) for 28 days significantly decreased SBP and DBP (Kazuya 
Kozuma et al., 2005); whilst in Dujaili et al., it was demonstrated that, following 7 days of 
supplementation with GCBE, SBP and DBP were significantly decreased (Al-Dujaili, Abuhajleh, 
& Al-Turk, 2016). However, contrastingly, Yeon et al., among others, have reported GCBE does 
not elicit any significant effect on blood pressure (Park, Kim, Lee, & Lee, 2010), and conclusions 
drawn from previous meta-analytical examinations may be regarded as premature, with only a 
small number of eligible studies analyzed (Onakpoya, Spencer, Thompson, & Heneghan, 2015). 
Given the proliferation in studies investigating GCBE supplementation, the purpose of this study 
is to determine the efficacy and effectiveness of GCBE supplementation on indices of blood 
pressure. 
 
Material and methods 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
were followed in the conducting of this study (Moher, Liberati, Tetzlaff, Altman, & Group, 2009). 
Search strategy 
The literature search was performed in four databases including PubMed/Medline, Scopus, the 
Cochrane Library, and Google Scholar to identify clinical trials that examined the effects of green 
coffee supplements on SBP and DBP up to February 2019. The merging of MESH and non- MESH 
terms were used as follows: ((("green coffee"[Title/Abstract]) OR "green coffee 
extract"[Title/Abstract])) AND ((("Clinical Trials as Topic"[Mesh] OR "Cross-Over 
Studies"[Mesh] OR "Double-Blind Method"[Mesh] OR "Single-Blind Method"[Mesh] OR 
"Random Allocation"[Mesh] OR RCT[Title/Abstract] OR "Intervention Studies"[Title/Abstract] 
OR "intervention"[Title/Abstract] OR "controlled trial"[Title/Abstract] OR 
"randomized"[Title/Abstract] OR "randomised"[Title/Abstract] OR "random"[Title/Abstract] OR 
"randomly"[Title/Abstract] OR "placebo"[Title/Abstract] OR "assignment"[Title/Abstract]))). 
Moreover, we conducted hand searches of all reference lists of eligible articles, and related reviews 
in order to avoid missing any relevant article.  
Eligibility criteria 
We considered studies that were: (1) randomized placebo-controlled trials with crossover or 
parallel designs (2) publications that were carried out on adult individuals more than 18 years old 
(3) those that reported sufficient data on baseline and final trials of SBP or/and DBP in both green 
coffee and control groups (4) studies that did the intervention with any green coffee species. We 
excluded articles if they; (1) were conducted on children, pregnant women or animals (2) were not 
placebo-controlled trials (3) did not reported sufficient information for the outcomes in green 
coffee or control groups (4) examined the effects of green coffee along with other components. 
Grey literature, including conference papers, dissertations, and patents were omitted for purposes 
of this study. 
Data extraction 
Two independent investigators (A.N and HKV) performed the study selection, and a third, senior 
researcher (C.C.) was present to resolve any disagreements. In case of absence of reporting data 
in the published studies, we emailed the corresponding author to obtain the required data. The 
following data were acquired from each study; first study author's name, year of publication, age 
and gender of subjects, trial duration, study location, type and dosage of green coffee supplements, 
study design, health status of participants, number of participants in each group, mean and SD of 
outcome measures at baseline, post-trial and/or changes in outcome measures from baseline to the 
end-of-study. If a study reported multiple data at diverse time points, only the most recent were 
included. 
Quality assessment 
Methodological quality and risk of bias of included studies was determined by using the Cochrane 
scoring system (Moher et al., 2009). This tool assesses possible sources of bias in randomized 
trials, including the random sequence generation; the concealment of allocation to conditions; the 
inhibition of awareness of the allocated intervention; blinding of outcome assessment, incomplete 
outcome data, selective reporting, and other biases. Three scores of yes, no, and unclear could be 
given to each above-mentioned item, which are referred as high risk, low risk, and unknown risk 
respectively 
Data synthesis and statistical analysis 
Mean change and standard deviation (SD) of the outcome measures were used to estimate the 
mean difference between the intervention group and the control group at follow-up. If data were 
reported in a different format, standard calculations were performed to derive the mean and SD 
(Higgins, 2011; Hozo, Djulbegovic, & Hozo, 2005). In order to estimate effect sizes, the random-
effects model (using DerSimonian-Laird method) was used and results were provided across 
weighted mean difference (WMD) and 95% CI. We conducted subgroup analysis to investigate 
potential sources of heterogeneity among the studies. The sensitivity analysis was performed using 
the leave-one-out method, to discover the impact of each study, individually, on the overall effect 
size. Publication bias was assessed by means of visual calculation of funnel plots and Egger’s 
tests(Egger, Smith, Schneider, & Minder, 1997). If any publication bias was detected, it was tested 
via the ‘trim and fill’ approach (Palmer, Peters, Sutton, & Moreno, 2008). All statistical analyses 
were implemented using Stata software (Stata Corp. College Station, Texas, USA).  
Results 
Study selection 
The initial database search returned 181 articles (in addition to 2 articles retrieved by a hand 
searching), and after duplicates were removed, 129 articles remained. After screening based on the 
title and abstract 26 articles yielded for full-text review. Finally, 5 articles (K. Kozuma, S. 
Tsuchiya, J. Kohori, T. Hase, & I. Tokimitsu, 2005; Ryuji Ochiai et al., 2004; Park et al., 2010; 
Roshan, Nikpayam, Sedaghat, & Sohrab, 2018; Yamaguchi et al., 2008) with 9 studies were 
included in this meta-analysis (Figure 1).  
Characteristics of the included studies 
The characteristics of the included studies are summarized in Table 1. These studies were 
published between 2004 and 2018 and were conducted in the Iran (Roshan et al., 2018), south 
Korea (Park et al., 2010), and Japan (K. Kozuma et al., 2005; Ryuji Ochiai et al., 2004; Yamaguchi 
et al., 2008). The follow-up period ranged from 4 to 16 weeks. Daily recommended dosage of 
green coffee varied between 46 and 800 mg in these studies. The design of all the included trials 
was parallel. All studies were done on both genders except for one trial that included women only 
(Park et al., 2010), and four studies on men only (K. Kozuma et al., 2005; Ryuji Ochiai et al., 
2004). The sample size in the included trials ranged from 31 (Ryuji Ochiai et al., 2004) to 72 
(Yamaguchi et al., 2008). Participants in include studies were patients with the metabolic 
syndrome (Roshan et al., 2018), healthy subjects (R. Ochiai et al., 2008; Park et al., 2010), and 
patients with hypertension (K. Kozuma et al., 2005; Yamaguchi et al., 2008). 
Quality assessment 
 Methodological quality and risk of bias of included studies was provided in Supplemental 
Table 1. Most studies demonstrated adequate quality for key factors (Kazuya Kozuma et al., 
2005; Park et al., 2010; Yamaguchi et al., 2008). Two have fair quality for blinding of outcome 




Effect of green coffee extract supplementation on SBP 
Nine studies including a total of 501 participants (case=251 and control=250) reported SBP as an 
outcome measure. Overall results from the random-effects model indicated that green coffee 
extract supplementation administration did result in significant change in SBP after green coffee 
supplementation WMD: -3.093 mmHg, 95% CI: -3.914, -2.273, p<0.001) with no significant 
heterogeneity among the studies (I2 = 0.0%, p = 0.454) (Figure2). In the subgroup analysis, we 
found that green coffee extract supplementation remained significant in hypertensive subjects, and 
metabolic syndrome patients. In addition, there was a greater significant reduction in SBP in 
studies with green coffee dosage ≥400 mg (WMD: -7.21 mmHg, 95% CI: -13.73, -0.69, p = 0.030) 
and a significant reduction with intervention duration ≤4 weeks (WMD: -3.12 mmHg, 95% CI: -
3.96, -2.27, p<0.001) (Supplemental figure 1).  
 
Effect of green coffee extract supplementation on DBP 
9 studies including a total of 501 participants (case=251, and control=250) reported DBP as an 
outcome measure. Combined results from the random-effects model indicated that DBP did change 
significantly following green coffee extract administration (WMD: -2.170 mmHg, 95% CI: -2.749, 
-1.590, p<0.001) with low heterogeneity among the studies (I2 = 46.5%, p = 0.060) (Figure 3). 
When, we conducted subgroup analyses based on health status; green coffee extract administration 
reduced DBP only in hypertensive subjects (WMD: -2.179 mmHg, 95% CI: -2.524, -1.834, 
p<0.001). In addition, green coffee extract administration reduced DBP in studies with intervention 
duration ≤4 weeks and green coffee dosage <400 mg (Supplementary figure 2). 
Sensitivity analysis 
To discover the impact of each single study on the combine effect size, we removed each trial from 
the analysis, step by step. We observed no significant effect of any individual study on the combine 
effect sizes of SBP and DBP (Supplementary figure 3). 
Publication bias 
Evaluation of publication bias by visual inspection of funnel plot demonstrated no evidence of 
publication bias in the meta-analysis of green coffee extract supplementation on SBP and DBP 
(Figure 4). 
Discussion 
Bioactive phytochemicals of coffee have gained prominence due to their reputed biological 
properties, including; antioxidant and anti-inflammatory activities, increased fatty acid oxidation 
and insulin sensitivity, modulation of glucose absorption and utilization, and antihypertensive 
effects (Godos et al., 2014; Sudeep, Venkatakrishna, Patel, & Shyamprasad, 2016). Although 
coffee contains numerous bioactive phytochemicals, the traditional coffee roasting process inhibits 
significant amounts of the phytochemicals that are purportedly responsible for the biological 
actions, such as chlorogenic acid (Esquivel & Jiménez, 2012). To ameliorate loss of some 
compounds with beneficial, health-eliciting effects, coffee can also be used as GCBE (Esquivel & 
Jiménez, 2012). Green coffee bean extract is comprised of unroasted coffee beans and contains 
higher amounts of bioactive phytochemicals than that for the usual roasted coffee that is generally 
consumed (Esquivel & Jiménez, 2012; Sarriá, Martínez-López, Mateos, & Bravo-Clemente, 
2016). The unroasted variant of coffee, the green coffee bean, has been purported to elicit 
numerous, potential, positive effects on indices of blood pressure. Indeed, GCBE has been shown 
to elicit anti-hypertensive effects in spontaneously hypertensive rats [9], and in mildly 
hypertensive humans [10]. Given the health burden globally associated with hypertension and 
cardiovascular disease, and the dearth of consensus on the efficacy of GCBE in reducing blood 
pressure, the aim of the present study was to determine the efficacy and effectiveness of GCBE 
supplementation on blood pressure. In the present meta-analysis, we summarized results from nine 
studies which examined the effects of GCBE supplementation on SBP and DBP in adults. Our 
results indicated that GCBE supplementation can significantly reduce SBP and DBP. Whilst in the 
subgroup analyses, we found significant reductions in SBP and DBP for patients with pre-existing 
hypertension, particularly at dosages of ≥400 mg. 
Polyphenols are abundant secondary metabolites in plants and are asserted to prevent, or 
at least ameliorate, diseases associated with oxidative stress and their associated complications. 
The glycosylated derivate forms of polyphenol, chlorogenic acids (ester of caffeic acid and quinic 
acid) are the principal polyphenol in coffee (Manach, Scalbert, Morand, Rémésy, & Jiménez, 
2004). There is agglomerative evidence that coffee positively impacts metabolic syndromes such 
as obesity, type 2 diabetes, atherosclerosis, and insulin-resistance (Dickson et al., 2015; Ding, 
Bhupathiraju, Chen, van Dam, & Hu, 2014; Ho et al., 2012). Moreover, many pharmacological 
studies regarding GCBE supplementation demonstrate that the chlorogenic acids in green coffee 
regulates hypertensive, vasoreactivity, and glucose metabolism (Blum, Lemaire, & Lafay, 2007; 
Kazuya Kozuma et al., 2005). Indeed, in the present study we highlight that GCBE 
supplementation can significantly reduce SBP and DBP, and when stratified by health status, 
GCBE remains effective in reducing SBP and DBP in patients with preexisting hypertension, but 
not metabolic syndrome. Onakpoya et al, (Onakpoya et al., 2015) previously reported that GCBE 
supplementation significantly reduces SBP and DBP; problematically, however, in Onakpoya et 
al, only five eligible studies were included, with only Asian populations represented and no 
stratification by health status (Onakpoya et al., 2015). Thus, the authors concluded SBP and DBP 
are reduced; however, in the present study we were able to include a larger sample, a more diverse 
population, and demonstrate that the hypotensive effects of GCBE supplementation, specific to 
DBP, are only evident in patients with preexisting hypertension and not metabolic syndrome; 
whilst both patient groups had favorable reductions in SBP. 
Hypertension is associated with a variety of serious consequences and comorbidities, 
including; kidney disease, diabetes, stroke, heart disease and many others. It has been reported that 
for each 2 mmHg rise in SBP, this corresponds to a 7% increased risk of mortality from heart 
disease, in addition to a 10% increased risk of stroke ("Overview | Hypertension in adults: 
diagnosis and management | Guidance | NICE," 2019). Consumption GCBE has been reported to 
reduce BP and BMI via its’ influence on 11β-HSD1 Enzyme Activity, through the reduction of the 
stress hormone level, cortisol ("Overview | Hypertension in adults: diagnosis and management | 
Guidance | NICE," 2019; Revuelta-Iniesta & Al-Dujaili, 2014). Mechanistically, CGAs are 
involved in the suppression of macrophage infiltration, and thus may be involved in blood vessel 
remodeling (Kanno et al., 2013). Furthermore, the blood pressure reducing properties of CGA 
constituents (caffeic or ferulic acid) have been studied in animals (Suzuki et al., 2002), where 
intravenous injections of these acids at higher relative doses revealed stronger hypotensive effects. 
Human studies have demonstrated that although there is inter-individual variability in the 
absorption and pharmacokinetics, CGA has high bioavailability when consumed orally (Farah, 
Monteiro, Donangelo, & Lafay, 2008; Monteiro, Farah, Perrone, Trugo, & Donangelo, 2007; 
Stalmach, Steiling, Williamson, & Crozier, 2010). Supporting the assertion of high bioavailability 
when orally consumed, , we found a greater reduction in SBP at dosages of ≥400 mg. 
Strength and limitations 
The primary strength of this study was that this meta-analysis provided a comprehensive 
overview of the effect of GCBE supplementation of blood pressure indices, far beyond evidence 
thus far, manifest in human-based RCTs; and given the potential influence on the treatment or 
management of hypertension, this is worthwhile endeavor. The evidence base, prior to this meta-
analysis, was relatively bereft of uniformity, with the preceding meta-analysis only including five 
studies of homogenous populations, and thus urgently required a summative, quantitative 
assessment, which we have provided. We demonstrated that there is sufficient evidence for GCBE 
supplementation to elicit positive effects on SBP and DBP. Another strength of the current meta-
analysis is the assimilation of the heterogeneous sample of participants, with a range of 
demographic statuses, ethnicities and ages. We were also able to stratify analyses based on both 
duration of supplementation and dosage, in addition to health status, thereby providing foresight 
into expected outcomes based on such information and highlighting that reductions in DBP may 
only be manifest in patients with preexisting hypertension, and not metabolic syndrome.  
Notwithstanding, the current study has some limitations. The extent to which concomitant 
lifestyle adjustments influenced the results seen in the meta-analyses is uncertain. Apart from 
coffee, CGA is available in a wide variety of foods including potatoes, fruits and peanuts; on the 
average, humans are thought to consume approximately 1g of CGA daily via food intake (Suzuki 
et al., 2006). Whether the extra amount of CGA consumed by trial participants led to an 
enhancement of its effect on blood pressure is not clear. The adverse event reports from the 
included studies suggest that CGA is generally safe. In a previous report, CGA consumption has 
been reported to increase plasma total homocysteine concentration, which is a risk factor for 
coronary heart disease (Olthof, Hollman, Zock, & Katan, 2001). 
The analyses were not restricted to solitarily include patients of one type, consequently, 
this permitted a larger number of studies and participants to be included for analyses, however 
could conceivably impact mechanism of action and effectiveness. Some included trials were small 
in sample size, and it has been demonstrated by Sterne et al. that it is probable for studies with 
small sample sizes to report bigger effect sizes in intervention arms than studies with larger 
participant pools (Sterne & Egger, 2001). Nevertheless, this was out of the operational control of 
the meta-analysis.  
Conclusion 
      The results of current meta-analysis study support the use of GCBE supplementation for the 
improvement of blood pressure indices, with sub-group analysis highlighting greater 
improvements in dosages of ≥400 mg. However, notwithstanding the positive effect elicited by 
GCBE supplementation for SBP cross health statuses, it is evident that for DBP, significant effects 
only remain in patients with preexisting hypertension, and not metabolic syndrome. Moreover, 
there appears no deleterious or adverse side effects manifest as a result of GCBE supplementation; 
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